SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation (Amendment)
$PRCT
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $70.00 | Overweight | Stephens |
| 7/7/2025 | Perform | Oppenheimer | |
| 12/2/2024 | $105.00 | Overweight | Morgan Stanley |
| 11/14/2024 | $95.00 | Hold | Jefferies |
| 8/11/2023 | $42.00 | Overweight | Piper Sandler |
| 5/31/2023 | Outperform | William Blair | |
| 10/31/2022 | Neutral | BTIG Research | |
| 10/25/2022 | $58.00 | Buy | Truist |
Stephens initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $70.00
Oppenheimer initiated coverage of PROCEPT BioRobotics with a rating of Perform
Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o
Larry L. Wood to join PROCEPT BioRobotics effective September 2, 2025Company confirms strong underlying business trends and pre-announces 2Q25 revenue of approximately $79.2 million, representing annual growth of 48% SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that Larry L. Wood will join the Company as president and CEO effective September 2, 2025. Dr. Reza Zadno will retire as president, CEO, and director effective September 1, 2025. Since 2020, Dr. Zadno has led the Company through significant growth
SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that three prostate cancer procedures in the WATER IV Prostate Cancer (PCa) Trial were successfully completed in an Ambulatory Surgery Center (ASC) using Aquablation® therapy by Dr. Rahul Mehan of East Valley Urology in Scottsdale, Arizona. WATER IV PCa is a U.S. FDA investigational device exemption (IDE) approved clinical study comparing Aquablation® therapy and radical prostatectomy for the treatment of localized prostate cancer. The study will evalua
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
SAN JOSE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2025. Recent Highlights Total revenue of $79.2 million for the second quarter of 2025, an increase of 48% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $43.1 million for the second quarter of 2025, an increase of 58% compared to the prior year period in 2024Sold 51 robotic systems in the U.S. in the second quarter of 2025U.S. system and rental revenue o
SAN JOSE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2025 after market close on Wednesday, August 6, 2025. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/apg8aowj Dial-in registration for sell-side research a
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit